I

(redirected from oropharyngeal cancer)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

I

Fifth letter of a Nasdaq stock symbol specifying that it is the third preferred bond of the company.

I

1. On a stock transaction table, a symbol indicating that a dividend was paid after a stock split.

2. A symbol appearing next to a bond listed on NASDAQ indicating that the bond is a company's third preferred bond. All NASDAQ listings use a four-letter abbreviation; if the letter "I" follows the abbreviation, this indicates that the security being traded is a third preferred bond.

i

Used in the dividend column of stock transaction tables to indicate that the dividend was paid after a stock dividend or split: Lehigh s.20i.
Mentioned in ?
References in periodicals archive ?
Currently, few dental hygienists are applying their HPV-related knowledge with patients; however, they consistently reported performing oral cancer screenings to detect oropharyngeal cancer.
All dental care professionals need to educate themselves and their patients about the relationship between oropharyngeal cancers, HPV, and risk factor management.
Practice setting and length of practice did not correlate with knowledge of the link between HPV and oropharyngeal cancer (Table 2, Table 3, p = 0.
The report reviews pipeline therapeutics for Oropharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
However, molecular information regarding HPV infection and its effect on oropharyngeal cancer as pertains to Hispanics in PR and those the US is very limited, despite the fact that the incidence of this malignancy is rather high in PR (3).
Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.
21) Vaccinating boys against HPV has been reported to be cost effective because it could reduce the high health care expenditures associated with treating oropharyngeal cancer.
When monitoring the population-level effect of HPV vaccination on oropharyngeal cancer occurrence in the United States, data on the incidence and type-specific prevalence of this disease are essential.
A snapshot of the global therapeutic scenario for Oropharyngeal Cancer.
incidence of oropharyngeal cancer since 1984 can be attributed to infection with the human papillomavirus (HPV), according to a new study.
Estimated costs per QALY also differed between calculations that included only diseases for which the vaccine is it indicated (cervical disease, vulvar/vaginal disease, genital warts, and anal cancer) and those that also included prevention of other HPV-related conditions for which the vaccine isn't indicated, including recurrent respiratory papillo-matosis, oropharyngeal cancer, and penile cancer.
Comparison between computed tomography and clinical evaluation in tumour/node stage and follow-up of oral cavity and oropharyngeal cancer.